Immunogenic antigens as therapeutic targets against myeloid leukaemic cells.
SPAG9 is a further new antigen that might be a candidate for clinical use. In particular the high frequency of mRNA expression in different solid tumours and haematological malignancies is a prerequisite for a potentially wide use. Most of the tested CML patients showed humoral immune responses against SPAG9. Nevertheless, specific CD8-positive T cell-responses and clinical efficacy analogue to the targets RHAMM or WT-1 have to be shown.
Hofmann
Susanne
S
Greiner
Jochen
J
D048868:Adaptor Proteins, Signal Transducing / Q000037:antagonists & inhibitors / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D015195:Drug Design; D005260:Female; D006801:Humans; D016233:Immunotherapy, Active; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D008297:Male; D014611:Vaccination
D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; C111047:SPAG9 protein, human